Business Context and Reporting Period
Relmada Therapeutics, Inc. filed a Form 8-K on February 6, 2019, reporting the entry into a Material Definitive Agreement. The filing addresses the resolution of ongoing litigation and the establishment of a new consulting relationship.
Key Financial Metrics and Agreements
- Settlement Payment: The Company agreed to pay Dr. Najib Babul a total of $500,000, with payment due by February 6, 2019.
- Share Cancellation: Dr. Babul agreed to cancel 303,392 shares of Company common stock, reducing the total issued and outstanding shares.
- Consulting Fees: A three-year Consulting Agreement was signed with an effective date of March 25, 2019. The fee is approximately $333,333 per year.
- Payment Terms: The entire three-year consulting fee is to be paid during 2019 in quarterly installments starting March 31, 2019. The Company considers this compensation fully earned upon execution.
- Interest Penalty: Late payments incur interest at the Wall Street Journal Prime Rate.
Material Changes and Litigation Resolution
The filing reports the dismissal with prejudice of all outstanding litigation between the Company and Dr. Babul, including claims in Case No. 2:15-cv-02937-GAM pending in the United States District Court for the Eastern District of Pennsylvania. This settlement includes a mutual release of all claims and a confidentiality agreement. Additionally, the Company issued a neutral reference letter and a statement concluding that Dr. Babul did not engage in wrongdoing during his employment.
Outlook, Risks, and Unusual Items
The Company has resolved a significant legal contingency, eliminating the risk of adverse judgment in the cited case. However, the agreement creates a substantial near-term cash outflow obligation, as the full three-year consulting fee ($1,000,000 total) is payable within the 2019 fiscal year. The filing does not provide specific data on the Company's current liquidity, cash flow, or debt levels to assess the impact of these payments.
Investor Verification Checklist
- Verify the Company's current cash and cash equivalents to confirm the ability to fund the $500,000 settlement and the $1,000,000 consulting fee obligation in 2019.
- Confirm the updated share count following the cancellation of 303,392 shares.
- Review the upcoming Form 10-Q for the quarter ended December 31, 2018, for the full text of the Settlement and Consulting Agreements.
- Assess the impact of the $1,000,000 expense recognition on the Company's 2019 net income and operating cash flow.